J&J beats profit estimates, lifts outlook on pharma unit strength

Johnson & Johnson reported slightly better-than-expected third quarter profit and raised its full-year forecast on Tuesday as increased demand for cancer drugs and immune disorder treatments powered strong results for its pharmaceutical unit.